Corbus Pharmaceuticals Reports Positive Clinical Data for CRB-701 & CRB-913, Plans Registrational HNSCC Study

summarizeSummary

Corbus Pharmaceuticals announced positive clinical data for its lead oncology asset CRB-701, with plans for registrational studies, and promising early data for its obesity candidate CRB-913, alongside a robust cash position.

check_boxKey Events

• CRB-701 Oncology Program Update

  The company reported positive safety and efficacy data for CRB-701 in HNSCC and cervical cancer from ESMO 2025 data, showing favorable profiles compared to peers.

• HNSCC Registrational Study Planned

  Corbus Pharmaceuticals plans to initiate a Phase 2/3 registrational study for CRB-701 monotherapy in HNSCC by mid-2026, following promising clinical results.

• CRB-913 Obesity Program Progress

  Phase 1a data for CRB-913 demonstrated emerging weight loss signals (2.9% placebo-adjusted at Day 14) and a favorable tolerability profile, leading to the ongoing Phase 1b study.

• Strong Cash Position

  The company reported $173 million in cash, cash equivalents, and investments as of November 3, 2025, indicating a significant financial runway for its development programs.

auto_awesomeAnalysis

Corbus Pharmaceuticals provided significant updates on its clinical pipeline, highlighting positive safety and efficacy data for CRB-701 in Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancer, with plans to initiate registrational studies for HNSCC. Early-stage data for CRB-913 in obesity also showed promising weight loss signals and a favorable tolerability profile, leading to the initiation of a Phase 1b study. Additionally, the company reported a strong cash position of $173 million, providing a substantial runway for its development programs.